$9.94
+0.33 (+3.43%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MSLE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 3 tracked-famous managers (Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC) · FINRA short interest 1.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsNCT07287189Safety of SAT-3247Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: SAT-3247, Placebo | Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies | 51 | 2027-03-31 | in 224 d | 2026-08-14 |
| An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101NCT06867107Treatment emergent adverse eventsOpen-label · Treatment | Phase 2 | Enrolling by invitation | Drug: SAT-3247 | Duchenne Muscular Dystrophy (DMD) | 10 | 2026-08-30 | in 11 d | 2026-04-23 |
| First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK CohortNCT06565208Incidence and severity of treatment emergent adverse eventsRandomized · Open-label · Treatment | Early Phase 1 | Completed | Drug: SAT-3247, matched placebo | Duchenne Muscular Dystrophy | 77 | 2025-04-28actual | — | 2025-05-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19